UCL School of Pharmacy, Centre for Behavioural Medicine, London, UK.
Department of Pharmacy & Pharmacology, University of Bath, Bath, UK.
J Crohns Colitis. 2020 Oct 5;14(10):1394-1404. doi: 10.1093/ecco-jcc/jjz034.
Interventions to improve adherence to medication may be more effective if tailored to the individual, addressing adherence-related beliefs about treatment and overcoming practical barriers to daily use. We evaluated whether an algorithm, tailoring support to address perceptual and practical barriers to adherence, reduced barriers and was acceptable to patients with inflammatory bowel disease [IBD].
Participants with IBD, prescribed azathioprine and/or mesalazine, were recruited via patient groups, social media, and hospital clinics and allocated to Intervention or Control Groups. The online intervention comprised messages tailored to address beliefs about IBD and maintenance treatment and to provide advice on overcoming practical difficulties with taking regular medication. The content was personalised to address specific perceptual and practical barriers identified by a pre-screening tool. Validated questionnaires assessed barriers to adherence and related secondary outcomes at baseline and at 1 and 3 months of follow-up.
A total of 329 participants were allocated to the Intervention [n = 153] and Control [n = 176] Groups; just under half [46.2%] completed follow-up. At 1 and 3 months, the Intervention Group had significantly fewer concerns about IBD medication [p ≤0.01]; and at three months, fewer doubts about treatment necessity, fewer reported practical barriers, and higher reported adherence [p <0.05]. Relative to controls at follow-up, the Intervention Group were more satisfied with information about IBD medicines, and viewed pharmaceuticals in general more positively. Questionnaires, interviews, and intervention usage indicated that the intervention was acceptable.
Personalised adherence support using a digital algorithm can help patients overcome perceptual barriers [doubts about treatment necessity and medication concerns] and practical barriers to adherence.
如果针对个体进行干预以改善药物依从性,针对与治疗相关的信念和克服日常使用的实际障碍,干预措施可能会更有效。我们评估了一种算法,通过定制支持来解决与依从性相关的认知和实际障碍,是否可以减少炎症性肠病(IBD)患者的障碍并被患者接受。
通过患者群体、社交媒体和医院诊所招募了 IBD 患者,他们正在服用硫唑嘌呤和/或美沙拉嗪,并将其分配到干预组或对照组。在线干预包括针对 IBD 和维持治疗相关信念的信息,以及有关克服定期服药实际困难的建议。内容是个性化的,以解决通过预筛选工具确定的特定认知和实际障碍。在基线和 1 个月和 3 个月的随访中,使用经过验证的问卷评估了对依从性的障碍和相关次要结果。
共有 329 名参与者被分配到干预组[n = 153]和对照组[n = 176];近一半[46.2%]完成了随访。在 1 个月和 3 个月时,干预组对 IBD 药物的担忧明显减少[p ≤0.01];在三个月时,治疗必要性的疑虑减少,报告的实际障碍减少,报告的依从性更高[p <0.05]。与随访时的对照组相比,干预组对 IBD 药物的信息更满意,对一般药物的看法更为积极。问卷调查、访谈和干预使用情况表明该干预措施是可以接受的。
使用数字算法进行个性化依从性支持可以帮助患者克服认知障碍[对治疗必要性和药物的疑虑]和依从性的实际障碍。